These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15613899)

  • 1. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.
    Woodward JK; Coleman RE; Holen I
    Anticancer Drugs; 2005 Jan; 16(1):11-9. PubMed ID: 15613899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor potential of bisphosphonates.
    Clézardin P
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis.
    Green JR; Clézardin P
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S3-9. PubMed ID: 12562045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
    Boissier S; Ferreras M; Peyruchaud O; Magnetto S; Ebetino FH; Colombel M; Delmas P; Delaissé JM; Clézardin P
    Cancer Res; 2000 Jun; 60(11):2949-54. PubMed ID: 10850442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects.
    Teixeira S; Branco L; Fernandes MH; Costa-Rodrigues J
    Mini Rev Med Chem; 2019; 19(12):988-998. PubMed ID: 31020940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL; Gnant M; Coleman RE
    Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
    Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
    J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
    J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct effects of bisphosphonates on breast cancer cells.
    Senaratne SG; Colston KW
    Breast Cancer Res; 2002; 4(1):18-23. PubMed ID: 11879555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
    Clézardin P; Ebetino FH; Fournier PG
    Cancer Res; 2005 Jun; 65(12):4971-4. PubMed ID: 15958534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antitumor effects of bisphosphonates.
    Clézardin P; Fournier P; Boissier S; Peyruchaud O
    Curr Med Chem; 2003 Jan; 10(2):173-80. PubMed ID: 12570716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.
    Daniele G; Giordano P; De Luca A; Piccirillo MC; Di Maio M; Del Giudice A; De Feo G; Bryce J; Lamura L; Vecchione A; Normanno N; Perrone F
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):299-307. PubMed ID: 21342047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
    Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
    J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
    Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
    Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
    Boissier S; Magnetto S; Frappart L; Cuzin B; Ebetino FH; Delmas PD; Clezardin P
    Cancer Res; 1997 Sep; 57(18):3890-4. PubMed ID: 9307266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.